Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 5Parasomnias 3Neoplasms 3Tuberous Sclerosis 2Smith-Magenis Syndrome 2Lung Neoplasms 2Autism Spectrum Disorder 2Angelman Syndrome 2Weight Loss 1Squamous Cell Carcinoma of Head and Neck 1Sleep Wake Disorders 1Sleep Disorders, Circadian Rhythm 1Relapsed Malignant Solid Tumor 1Radiodermatitis 1Radiation Injuries 1Polycystic Ovary Syndrome 1Pain 1Neoplasm Metastasis 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Fatigue 1Depression 1Delirium 1Carcinoma, Non-Small-Cell Lung 1Cachexia 1Brain Neoplasms 1Barrett Esophagus 1Anorexia 1

Interventions

Melatonin 2Lovastatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Autism Spectrum Disorder × Melatonin × Clear all
NCT01906866 2024-04-23

Efficacy and Safety of CircadinĀ® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities

Neurim Pharmaceuticals Ltd.

Phase 3 Completed
125 enrolled 22 charts

Autism Spectrum Disorder, Sleep Wake Disorders, Tuberous Sclerosis, Angelman Syndrome, Parasomnias, Smith-Magenis Syndrome

NCT01903681 2014-04-04

Assessment of the Pharmacokinetics of CircadinĀ® in Children With Neurodevelopmental Disorders and Sleep Disturbances

Neurim Pharmaceuticals Ltd.

Phase 1 Completed
16 enrolled

Autism Spectrum Disorder, Tuberous Sclerosis, Angelman Syndrome, Parasomnias, Smith-Magenis Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚔